Global Pulmonary Hypertension Drug Market

Pulmonary Hypertension Drug Comprehensive Study by Type (IK-3001, Sildenafil Citrate IMD, IK-7002, Riociguat, SAR-407899, Others), Application (Early-Stage Drug Candidates (Phase I & Phase II), Late-Stage Drug Candidates (Phase III & Registration Phase))) Players and Region - Global Market Outlook to 2026

Pulmonary Hypertension Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Increasing geriatric population across the globe over the last decade and increasing adoption of unhealthier lifestyles might lead to several health issues such as pulmonary hypertension (PAH). In addition to this, consumption of alcohol, tobacco, and other drugs has been robustly increased over the past few decades leading to increased prevalence of PAH. Thus, it will ultimately lead to lucrative growth of PAH drugs market. There are mainly four classes of approved drug types available in the market with 13 approved products across them. However, upsurging technological advancements and robust research& development will introduce a variety of drugs on curing PAH.
This growth is primarily driven by Increasing Geriatric Population across the Globe leading to Increased Instances of Pulmonary Hypertension and Increasing Adoption of Unhealthier LifeStyle Leading to Upsurging Probability.

Globally, a noticeable market trend is evident Growing Consumption of Alcohol, Tobacco and Unhealthier Food Products leading to Increased Instances . The Pharmaceuticals sector in the Europe region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Sanofi S.A. (France), Vectura Group Plc (United Kingdom), Bayer AG (Germany), Mallinckrodt Pharmaceuticals (United Kingdom), Proreo Pharma AG (Switzerland), Vicore Pharma AB (Sweden), Biolab Sanus Farmaceutica Ltda. (Brazil), Actelion Pharmaceuticals Ltd. (Switzerland), Daiichi Sankyo Company (Japan), GlaxoSmithKline (United Kingdom) and Novartis International AG (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

On June 18, 2019, Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. The collaboration aims to change how Sanofi develops new treatments and will focus on three key objectives: to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

Market Drivers
  • Increasing Geriatric Population across the Globe leading to Increased Instances of Pulmonary Hypertension
  • Increasing Adoption of Unhealthier LifeStyle Leading to Upsurging Probability

Market Trend
  • Growing Consumption of Alcohol, Tobacco and Unhealthier Food Products leading to Increased Instances
  • Continuous Research and Developments in Pulmonary Hypertension Drug Development

Restraints
  • Growing Manufacturing Complexities in the Pharmaceutical Industry
  • Lack of Availability of Raw Materials required for Manufacturing Pulmonary Hypertension Drugs

Opportunities
Growing Government Reimbursements in Developing Orphan Drugs and Minimized International Trade Barriers for Pharmaceutical Products
Challenges
Stringent Government Regulations on Pharmaceutical Production

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Pulmonary Hypertension Drug Study Sheds Light on
— The Pulmonary Hypertension Drug Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Pulmonary Hypertension Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Pulmonary Hypertension Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • IK-3001
  • Sildenafil Citrate IMD
  • IK-7002
  • Riociguat
  • SAR-407899
  • Others
By Application
  • Early-Stage Drug Candidates (Phase I & Phase II)
  • Late-Stage Drug Candidates (Phase III & Registration Phase))
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population across the Globe leading to Increased Instances of Pulmonary Hypertension
      • 3.2.2. Increasing Adoption of Unhealthier LifeStyle Leading to Upsurging Probability
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations on Pharmaceutical Production
    • 3.4. Market Trends
      • 3.4.1. Growing Consumption of Alcohol, Tobacco and Unhealthier Food Products leading to Increased Instances
      • 3.4.2. Continuous Research and Developments in Pulmonary Hypertension Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pulmonary Hypertension Drug, by Type, Application and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pulmonary Hypertension Drug (Value)
      • 5.2.1. Global Pulmonary Hypertension Drug by: Type (Value)
        • 5.2.1.1. IK-3001
        • 5.2.1.2. Sildenafil Citrate IMD
        • 5.2.1.3. IK-7002
        • 5.2.1.4. Riociguat
        • 5.2.1.5. SAR-407899
        • 5.2.1.6. Others
      • 5.2.2. Global Pulmonary Hypertension Drug by: Application (Value)
        • 5.2.2.1. Early-Stage Drug Candidates (Phase I & Phase II)
        • 5.2.2.2. Late-Stage Drug Candidates (Phase III & Registration Phase))
      • 5.2.3. Global Pulmonary Hypertension Drug Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Pulmonary Hypertension Drug (Volume)
      • 5.3.1. Global Pulmonary Hypertension Drug by: Type (Volume)
        • 5.3.1.1. IK-3001
        • 5.3.1.2. Sildenafil Citrate IMD
        • 5.3.1.3. IK-7002
        • 5.3.1.4. Riociguat
        • 5.3.1.5. SAR-407899
        • 5.3.1.6. Others
      • 5.3.2. Global Pulmonary Hypertension Drug by: Application (Volume)
        • 5.3.2.1. Early-Stage Drug Candidates (Phase I & Phase II)
        • 5.3.2.2. Late-Stage Drug Candidates (Phase III & Registration Phase))
      • 5.3.3. Global Pulmonary Hypertension Drug Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Pulmonary Hypertension Drug (Price)
      • 5.4.1. Global Pulmonary Hypertension Drug by: Type (Price)
  • 6. Pulmonary Hypertension Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A. (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Vectura Group Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Proreo Pharma AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Vicore Pharma AB (Sweden)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biolab Sanus Farmaceutica Ltda. (Brazil)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Actelion Pharmaceuticals Ltd. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Daiichi Sankyo Company (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis International AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Pulmonary Hypertension Drug Sale, by Type, Application and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pulmonary Hypertension Drug (Value)
      • 7.2.1. Global Pulmonary Hypertension Drug by: Type (Value)
        • 7.2.1.1. IK-3001
        • 7.2.1.2. Sildenafil Citrate IMD
        • 7.2.1.3. IK-7002
        • 7.2.1.4. Riociguat
        • 7.2.1.5. SAR-407899
        • 7.2.1.6. Others
      • 7.2.2. Global Pulmonary Hypertension Drug by: Application (Value)
        • 7.2.2.1. Early-Stage Drug Candidates (Phase I & Phase II)
        • 7.2.2.2. Late-Stage Drug Candidates (Phase III & Registration Phase))
      • 7.2.3. Global Pulmonary Hypertension Drug Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Pulmonary Hypertension Drug (Volume)
      • 7.3.1. Global Pulmonary Hypertension Drug by: Type (Volume)
        • 7.3.1.1. IK-3001
        • 7.3.1.2. Sildenafil Citrate IMD
        • 7.3.1.3. IK-7002
        • 7.3.1.4. Riociguat
        • 7.3.1.5. SAR-407899
        • 7.3.1.6. Others
      • 7.3.2. Global Pulmonary Hypertension Drug by: Application (Volume)
        • 7.3.2.1. Early-Stage Drug Candidates (Phase I & Phase II)
        • 7.3.2.2. Late-Stage Drug Candidates (Phase III & Registration Phase))
      • 7.3.3. Global Pulmonary Hypertension Drug Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Pulmonary Hypertension Drug (Price)
      • 7.4.1. Global Pulmonary Hypertension Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pulmonary Hypertension Drug: by Type(USD Million)
  • Table 2. Pulmonary Hypertension Drug IK-3001 , by Region USD Million (2015-2020)
  • Table 3. Pulmonary Hypertension Drug Sildenafil Citrate IMD , by Region USD Million (2015-2020)
  • Table 4. Pulmonary Hypertension Drug IK-7002 , by Region USD Million (2015-2020)
  • Table 5. Pulmonary Hypertension Drug Riociguat , by Region USD Million (2015-2020)
  • Table 6. Pulmonary Hypertension Drug SAR-407899 , by Region USD Million (2015-2020)
  • Table 7. Pulmonary Hypertension Drug Others , by Region USD Million (2015-2020)
  • Table 8. Pulmonary Hypertension Drug: by Application(USD Million)
  • Table 9. Pulmonary Hypertension Drug Early-Stage Drug Candidates (Phase I & Phase II) , by Region USD Million (2015-2020)
  • Table 10. Pulmonary Hypertension Drug Late-Stage Drug Candidates (Phase III & Registration Phase)) , by Region USD Million (2015-2020)
  • Table 11. South America Pulmonary Hypertension Drug, by Country USD Million (2015-2020)
  • Table 12. South America Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 13. South America Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 14. Brazil Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 15. Brazil Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 16. Argentina Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 17. Argentina Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 19. Rest of South America Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 20. Asia Pacific Pulmonary Hypertension Drug, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 22. Asia Pacific Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 23. China Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 24. China Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 25. Japan Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 26. Japan Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 27. India Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 28. India Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 29. South Korea Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 30. South Korea Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 31. Taiwan Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 32. Taiwan Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 33. Australia Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 34. Australia Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 37. Europe Pulmonary Hypertension Drug, by Country USD Million (2015-2020)
  • Table 38. Europe Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 39. Europe Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 40. Germany Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 41. Germany Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 42. France Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 43. France Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 44. Italy Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 45. Italy Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 47. United Kingdom Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 48. Netherlands Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 49. Netherlands Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 51. Rest of Europe Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 52. MEA Pulmonary Hypertension Drug, by Country USD Million (2015-2020)
  • Table 53. MEA Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 54. MEA Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 55. Middle East Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 56. Middle East Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 57. Africa Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 58. Africa Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 59. North America Pulmonary Hypertension Drug, by Country USD Million (2015-2020)
  • Table 60. North America Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 61. North America Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 62. United States Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 63. United States Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 64. Canada Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 65. Canada Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 66. Mexico Pulmonary Hypertension Drug, by Type USD Million (2015-2020)
  • Table 67. Mexico Pulmonary Hypertension Drug, by Application USD Million (2015-2020)
  • Table 68. Pulmonary Hypertension Drug Sales: by Type(K Units)
  • Table 69. Pulmonary Hypertension Drug Sales IK-3001 , by Region K Units (2015-2020)
  • Table 70. Pulmonary Hypertension Drug Sales Sildenafil Citrate IMD , by Region K Units (2015-2020)
  • Table 71. Pulmonary Hypertension Drug Sales IK-7002 , by Region K Units (2015-2020)
  • Table 72. Pulmonary Hypertension Drug Sales Riociguat , by Region K Units (2015-2020)
  • Table 73. Pulmonary Hypertension Drug Sales SAR-407899 , by Region K Units (2015-2020)
  • Table 74. Pulmonary Hypertension Drug Sales Others , by Region K Units (2015-2020)
  • Table 75. Pulmonary Hypertension Drug Sales: by Application(K Units)
  • Table 76. Pulmonary Hypertension Drug Sales Early-Stage Drug Candidates (Phase I & Phase II) , by Region K Units (2015-2020)
  • Table 77. Pulmonary Hypertension Drug Sales Late-Stage Drug Candidates (Phase III & Registration Phase)) , by Region K Units (2015-2020)
  • Table 78. South America Pulmonary Hypertension Drug Sales, by Country K Units (2015-2020)
  • Table 79. South America Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 80. South America Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 81. Brazil Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 82. Brazil Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 83. Argentina Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 84. Argentina Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 85. Rest of South America Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 86. Rest of South America Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 87. Asia Pacific Pulmonary Hypertension Drug Sales, by Country K Units (2015-2020)
  • Table 88. Asia Pacific Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 89. Asia Pacific Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 90. China Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 91. China Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 92. Japan Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 93. Japan Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 94. India Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 95. India Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 96. South Korea Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 97. South Korea Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 98. Taiwan Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 99. Taiwan Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 100. Australia Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 101. Australia Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 102. Rest of Asia-Pacific Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 103. Rest of Asia-Pacific Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 104. Europe Pulmonary Hypertension Drug Sales, by Country K Units (2015-2020)
  • Table 105. Europe Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 106. Europe Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 107. Germany Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 108. Germany Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 109. France Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 110. France Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 111. Italy Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 112. Italy Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 113. United Kingdom Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 114. United Kingdom Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 115. Netherlands Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 116. Netherlands Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 117. Rest of Europe Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 118. Rest of Europe Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 119. MEA Pulmonary Hypertension Drug Sales, by Country K Units (2015-2020)
  • Table 120. MEA Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 121. MEA Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 122. Middle East Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 123. Middle East Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 124. Africa Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 125. Africa Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 126. North America Pulmonary Hypertension Drug Sales, by Country K Units (2015-2020)
  • Table 127. North America Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 128. North America Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 129. United States Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 130. United States Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 131. Canada Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 132. Canada Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 133. Mexico Pulmonary Hypertension Drug Sales, by Type K Units (2015-2020)
  • Table 134. Mexico Pulmonary Hypertension Drug Sales, by Application K Units (2015-2020)
  • Table 135. Pulmonary Hypertension Drug: by Type(USD/Units)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Pulmonary Hypertension Drug: by Type(USD Million)
  • Table 148. Pulmonary Hypertension Drug IK-3001 , by Region USD Million (2021-2026)
  • Table 149. Pulmonary Hypertension Drug Sildenafil Citrate IMD , by Region USD Million (2021-2026)
  • Table 150. Pulmonary Hypertension Drug IK-7002 , by Region USD Million (2021-2026)
  • Table 151. Pulmonary Hypertension Drug Riociguat , by Region USD Million (2021-2026)
  • Table 152. Pulmonary Hypertension Drug SAR-407899 , by Region USD Million (2021-2026)
  • Table 153. Pulmonary Hypertension Drug Others , by Region USD Million (2021-2026)
  • Table 154. Pulmonary Hypertension Drug: by Application(USD Million)
  • Table 155. Pulmonary Hypertension Drug Early-Stage Drug Candidates (Phase I & Phase II) , by Region USD Million (2021-2026)
  • Table 156. Pulmonary Hypertension Drug Late-Stage Drug Candidates (Phase III & Registration Phase)) , by Region USD Million (2021-2026)
  • Table 157. South America Pulmonary Hypertension Drug, by Country USD Million (2021-2026)
  • Table 158. South America Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 159. South America Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 160. Brazil Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 161. Brazil Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 162. Argentina Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 163. Argentina Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 165. Rest of South America Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 166. Asia Pacific Pulmonary Hypertension Drug, by Country USD Million (2021-2026)
  • Table 167. Asia Pacific Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 168. Asia Pacific Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 169. China Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 170. China Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 171. Japan Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 172. Japan Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 173. India Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 174. India Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 175. South Korea Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 176. South Korea Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 177. Taiwan Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 178. Taiwan Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 179. Australia Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 180. Australia Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 181. Rest of Asia-Pacific Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 182. Rest of Asia-Pacific Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 183. Europe Pulmonary Hypertension Drug, by Country USD Million (2021-2026)
  • Table 184. Europe Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 185. Europe Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 186. Germany Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 187. Germany Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 188. France Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 189. France Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 190. Italy Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 191. Italy Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 192. United Kingdom Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 193. United Kingdom Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 194. Netherlands Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 195. Netherlands Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 196. Rest of Europe Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 197. Rest of Europe Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 198. MEA Pulmonary Hypertension Drug, by Country USD Million (2021-2026)
  • Table 199. MEA Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 200. MEA Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 201. Middle East Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 202. Middle East Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 203. Africa Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 204. Africa Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 205. North America Pulmonary Hypertension Drug, by Country USD Million (2021-2026)
  • Table 206. North America Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 207. North America Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 208. United States Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 209. United States Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 210. Canada Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 211. Canada Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 212. Mexico Pulmonary Hypertension Drug, by Type USD Million (2021-2026)
  • Table 213. Mexico Pulmonary Hypertension Drug, by Application USD Million (2021-2026)
  • Table 214. Pulmonary Hypertension Drug Sales: by Type(K Units)
  • Table 215. Pulmonary Hypertension Drug Sales IK-3001 , by Region K Units (2021-2026)
  • Table 216. Pulmonary Hypertension Drug Sales Sildenafil Citrate IMD , by Region K Units (2021-2026)
  • Table 217. Pulmonary Hypertension Drug Sales IK-7002 , by Region K Units (2021-2026)
  • Table 218. Pulmonary Hypertension Drug Sales Riociguat , by Region K Units (2021-2026)
  • Table 219. Pulmonary Hypertension Drug Sales SAR-407899 , by Region K Units (2021-2026)
  • Table 220. Pulmonary Hypertension Drug Sales Others , by Region K Units (2021-2026)
  • Table 221. Pulmonary Hypertension Drug Sales: by Application(K Units)
  • Table 222. Pulmonary Hypertension Drug Sales Early-Stage Drug Candidates (Phase I & Phase II) , by Region K Units (2021-2026)
  • Table 223. Pulmonary Hypertension Drug Sales Late-Stage Drug Candidates (Phase III & Registration Phase)) , by Region K Units (2021-2026)
  • Table 224. South America Pulmonary Hypertension Drug Sales, by Country K Units (2021-2026)
  • Table 225. South America Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 226. South America Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 227. Brazil Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 228. Brazil Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 229. Argentina Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 230. Argentina Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 231. Rest of South America Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 232. Rest of South America Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 233. Asia Pacific Pulmonary Hypertension Drug Sales, by Country K Units (2021-2026)
  • Table 234. Asia Pacific Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 235. Asia Pacific Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 236. China Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 237. China Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 238. Japan Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 239. Japan Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 240. India Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 241. India Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 242. South Korea Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 243. South Korea Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 244. Taiwan Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 245. Taiwan Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 246. Australia Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 247. Australia Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 248. Rest of Asia-Pacific Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 249. Rest of Asia-Pacific Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 250. Europe Pulmonary Hypertension Drug Sales, by Country K Units (2021-2026)
  • Table 251. Europe Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 252. Europe Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 253. Germany Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 254. Germany Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 255. France Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 256. France Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 257. Italy Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 258. Italy Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 259. United Kingdom Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 260. United Kingdom Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 261. Netherlands Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 262. Netherlands Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 263. Rest of Europe Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 264. Rest of Europe Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 265. MEA Pulmonary Hypertension Drug Sales, by Country K Units (2021-2026)
  • Table 266. MEA Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 267. MEA Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 268. Middle East Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 269. Middle East Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 270. Africa Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 271. Africa Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 272. North America Pulmonary Hypertension Drug Sales, by Country K Units (2021-2026)
  • Table 273. North America Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 274. North America Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 275. United States Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 276. United States Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 277. Canada Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 278. Canada Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 279. Mexico Pulmonary Hypertension Drug Sales, by Type K Units (2021-2026)
  • Table 280. Mexico Pulmonary Hypertension Drug Sales, by Application K Units (2021-2026)
  • Table 281. Pulmonary Hypertension Drug: by Type(USD/Units)
  • Table 282. Research Programs/Design for This Report
  • Table 283. Key Data Information from Secondary Sources
  • Table 284. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pulmonary Hypertension Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Pulmonary Hypertension Drug: by Application USD Million (2015-2020)
  • Figure 6. South America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 7. Asia Pacific Pulmonary Hypertension Drug Share (%), by Country
  • Figure 8. Europe Pulmonary Hypertension Drug Share (%), by Country
  • Figure 9. MEA Pulmonary Hypertension Drug Share (%), by Country
  • Figure 10. North America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 11. Global Pulmonary Hypertension Drug: by Type K Units (2015-2020)
  • Figure 12. Global Pulmonary Hypertension Drug: by Application K Units (2015-2020)
  • Figure 13. South America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 14. Asia Pacific Pulmonary Hypertension Drug Share (%), by Country
  • Figure 15. Europe Pulmonary Hypertension Drug Share (%), by Country
  • Figure 16. MEA Pulmonary Hypertension Drug Share (%), by Country
  • Figure 17. North America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 18. Global Pulmonary Hypertension Drug: by Type USD/Units (2015-2020)
  • Figure 19. Global Pulmonary Hypertension Drug share by Players 2020 (%)
  • Figure 20. Global Pulmonary Hypertension Drug share by Players (Top 3) 2020(%)
  • Figure 21. Global Pulmonary Hypertension Drug share by Players (Top 5) 2020(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 25. Vectura Group Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Vectura Group Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 29. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Proreo Pharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Proreo Pharma AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Vicore Pharma AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 34. Vicore Pharma AB (Sweden) Revenue: by Geography 2020
  • Figure 35. Biolab Sanus Farmaceutica Ltda. (Brazil) Revenue, Net Income and Gross profit
  • Figure 36. Biolab Sanus Farmaceutica Ltda. (Brazil) Revenue: by Geography 2020
  • Figure 37. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 39. Daiichi Sankyo Company (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Daiichi Sankyo Company (Japan) Revenue: by Geography 2020
  • Figure 41. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 43. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 45. Global Pulmonary Hypertension Drug: by Type USD Million (2021-2026)
  • Figure 46. Global Pulmonary Hypertension Drug: by Application USD Million (2021-2026)
  • Figure 47. South America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 48. Asia Pacific Pulmonary Hypertension Drug Share (%), by Country
  • Figure 49. Europe Pulmonary Hypertension Drug Share (%), by Country
  • Figure 50. MEA Pulmonary Hypertension Drug Share (%), by Country
  • Figure 51. North America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 52. Global Pulmonary Hypertension Drug: by Type K Units (2021-2026)
  • Figure 53. Global Pulmonary Hypertension Drug: by Application K Units (2021-2026)
  • Figure 54. South America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 55. Asia Pacific Pulmonary Hypertension Drug Share (%), by Country
  • Figure 56. Europe Pulmonary Hypertension Drug Share (%), by Country
  • Figure 57. MEA Pulmonary Hypertension Drug Share (%), by Country
  • Figure 58. North America Pulmonary Hypertension Drug Share (%), by Country
  • Figure 59. Global Pulmonary Hypertension Drug: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Sanofi S.A. (France)
  • Vectura Group Plc (United Kingdom)
  • Bayer AG (Germany)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • Proreo Pharma AG (Switzerland)
  • Vicore Pharma AB (Sweden)
  • Biolab Sanus Farmaceutica Ltda. (Brazil)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Daiichi Sankyo Company (Japan)
  • GlaxoSmithKline (United Kingdom)
  • Novartis International AG (Switzerland)
Additional players considered in the study are as follows:
United Therapeutics Corporation (United States) , Merck & Co., Inc. (United States) , Northern Therapeutics Inc (Canada) , Pfizer Inc. (United States) , PhaseBio Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Mar 2022 240 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pulmonary Hypertension Drug Market Quantitative research analysis
Global Pulmonary Hypertension Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Pulmonary Hypertension Drug market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Pulmonary Hypertension Drug market are Sanofi S.A. (France), Vectura Group Plc (United Kingdom), Bayer AG (Germany), Mallinckrodt Pharmaceuticals (United Kingdom), Proreo Pharma AG (Switzerland), Vicore Pharma AB (Sweden), Biolab Sanus Farmaceutica Ltda. (Brazil), Actelion Pharmaceuticals Ltd. (Switzerland), Daiichi Sankyo Company (Japan), GlaxoSmithKline (United Kingdom) and Novartis International AG (Switzerland), to name a few.
Europe is dominating the Pulmonary Hypertension Drug Market.

Know More About Global Pulmonary Hypertension Drug Market Report?

Have a Query? Click Here

Other Related Reports

Pharmaceutical Filtration Comprehensive Study by Type (Membrane Filters {MCE Membrane Filters, Coated Cellulose Acetate Membrane Filters, Nylon Membrane Filters, PTFE Membrane Filters, PVDF Membrane...
$ 3750
Hemophilia Drugs Comprehensive Study by Type (Hemlibra, Benefix, Advate, Novoseven RT, Eloctate, Humate-P, Others), Application (Recombinant Therapies, Plasma-Derived Therapies), Distribution Channel...
$ 3750
Methotrexate Comprehensive Study by Type (Tablet, Injection), Application (Cancer, Arthritis, Auto-Immune Diseases, Others), Sales Channel (Pharmacy Stores, Online Pharmacies), Dosage (5 mg, 7.5 mg, ...
$ 3450
Effervescent Products Comprehensive Study by Type (Prescription-Based, Daily-Use), Application (Pharmaceuticals, Functional Foods (Probiotics, Dietary Supplements, Electrolytes & Energy Boosting Supp...
$ 3750
Ibrutinib Comprehensive Study by Application (Chronic Lymphocytic Leukaemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL), Multiple Myeloma (MM), Follicular Lymphoma (FL), ...
$ 3650
Paclitaxel Comprehensive Study by Type (Natural Paclitaxel, Semi-synthetic Paclitaxel), Application (Breast Cancer, Ovarian Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Othe...
$ 3450